- Axplora has inaugurated a new 4,000 sqm production block at its US FDA-inspected PharmaZell site in Vizag, India.
- The four-floor facility will manufacture UDCA and is equipped for advanced enzymatic redox chemistry processes.
Axplora has inaugurated a new production block at its US FDA-inspected PharmaZell site in Vizag, India. The 4,000 square metre, four-floor facility was officially opened on 28 January 2026 and expands the company’s API manufacturing footprint.
The new block will manufacture ursodeoxycholic acid (UDCA), an active pharmaceutical ingredient used in medicines for chronic liver and biliary diseases. The expansion supports Axplora’s continued investment in API manufacturing and extends its global production capabilities.
According to the company, the facility has been designed as a center for advanced enzymatic redox chemistry. It is equipped with ultrafiltration, centrifugation, tumble drying, milling, and micronization technologies to support precision-driven production processes.
Axplora stated that the expansion builds on 75 years of PharmaZell expertise and strengthens its portfolio of 35 APIs and more than 20 patent families. The new site reinforces the company’s capabilities in API contract manufacturing for global pharmaceutical customers.
